BRPI0908276A2 - Métodos de tratar dor inflamatória - Google Patents

Métodos de tratar dor inflamatória

Info

Publication number
BRPI0908276A2
BRPI0908276A2 BRPI0908276-0A BRPI0908276A BRPI0908276A2 BR PI0908276 A2 BRPI0908276 A2 BR PI0908276A2 BR PI0908276 A BRPI0908276 A BR PI0908276A BR PI0908276 A2 BRPI0908276 A2 BR PI0908276A2
Authority
BR
Brazil
Prior art keywords
methods
inflammatory pain
treating inflammatory
treating
pain
Prior art date
Application number
BRPI0908276-0A
Other languages
English (en)
Inventor
Laura Corradini
Kristian Todd Poulsen
David Louis Shelton
Joerg Zeller
Ian Machin
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40823474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908276(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0908276A2 publication Critical patent/BRPI0908276A2/pt
Publication of BRPI0908276B1 publication Critical patent/BRPI0908276B1/pt
Publication of BRPI0908276B8 publication Critical patent/BRPI0908276B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0908276A 2008-03-04 2009-03-03 uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite BRPI0908276B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3356808P 2008-03-04 2008-03-04
US61/033,568 2008-03-04
PCT/IB2009/050849 WO2009109908A1 (en) 2008-03-04 2009-03-03 Methods of treating inflammatory pain

Publications (3)

Publication Number Publication Date
BRPI0908276A2 true BRPI0908276A2 (pt) 2015-08-18
BRPI0908276B1 BRPI0908276B1 (pt) 2020-11-10
BRPI0908276B8 BRPI0908276B8 (pt) 2021-05-25

Family

ID=40823474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908276A BRPI0908276B8 (pt) 2008-03-04 2009-03-03 uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite

Country Status (19)

Country Link
US (6) US8298536B2 (pt)
EP (2) EP3115062A1 (pt)
JP (3) JP5745861B2 (pt)
KR (1) KR101304085B1 (pt)
CN (2) CN106110321A (pt)
AU (1) AU2009220897B2 (pt)
BR (1) BRPI0908276B8 (pt)
CA (1) CA2716799C (pt)
DK (1) DK2265288T3 (pt)
ES (1) ES2584907T3 (pt)
HK (1) HK1232130A1 (pt)
IL (1) IL207439B (pt)
MX (1) MX2010009724A (pt)
NZ (1) NZ587297A (pt)
PL (1) PL2265288T3 (pt)
PT (1) PT2265288T (pt)
RU (1) RU2467765C2 (pt)
WO (1) WO2009109908A1 (pt)
ZA (1) ZA201006070B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3534353B2 (ja) 1994-03-08 2004-06-07 ミサワホーム株式会社 建物ユニットの耐火構造
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
ES2584907T3 (es) * 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
US9346742B2 (en) * 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
RU2535095C2 (ru) * 2013-01-09 2014-12-10 Федеральное государственное бюджетное учреждение науки "Институт токсикологии Федерального медико-биологического агентства" Композиция для трансдермальной доставки в организм лекарственных веществ и лекарственная форма на ее основе
KR101439032B1 (ko) * 2013-06-13 2014-09-05 동아에스티 주식회사 피록시캄과 히알루론산을 포함하는 골관절염 치료를 위한 액상 조성물
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) * 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JP6508670B2 (ja) * 2014-12-26 2019-05-08 国立大学法人広島大学 軟骨変性抑制剤
TWI728953B (zh) 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
WO2017031214A1 (en) * 2015-08-19 2017-02-23 University Of Iowa Research Foundation Preventative therapy for post-traumatic osteoarthritis
US20190031748A1 (en) 2016-01-28 2019-01-31 Eli Lilly And Company Cgrp antibodies and uses thereof
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US11771662B2 (en) 2017-09-05 2023-10-03 Kansas State University Research Foundation Analgesic formulation for control of pain in dogs
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
EP3774881A1 (en) 2018-04-02 2021-02-17 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
PE20211707A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
US12624015B2 (en) 2019-06-24 2026-05-12 University Of Iowa Research Foundation JNK inhibitors as anticancer agents
WO2021015342A1 (ko) * 2019-07-24 2021-01-28 의료법인 성광의료재단 Trpv4 길항제를 포함하는 척수 손상 예방 또는 치료용 조성물
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
CN112142838B (zh) * 2020-07-23 2021-11-16 杭州傲锐生物医药科技有限公司 一种卡利普多人工抗原及其多抗和应用
CN115181099B (zh) * 2021-04-02 2024-01-16 南京舒鹏生物科技有限公司 一种醌类化合物及其药学应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
AU721035C (en) 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA04002562A (es) * 2001-09-19 2004-05-31 Altana Pharma Ag Combinacion de un pde-4 y nsaid.
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2003093472A2 (de) * 2002-05-06 2003-11-13 Grünenthal GmbH Cgrp bindende nukleinsäuren
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2433251T5 (es) * 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
US8071770B2 (en) * 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
ES2584907T3 (es) * 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio

Also Published As

Publication number Publication date
WO2009109908A8 (en) 2010-08-19
CN106110321A (zh) 2016-11-16
US20180305443A1 (en) 2018-10-25
JP2015145420A (ja) 2015-08-13
JP2017105835A (ja) 2017-06-15
US20110054150A1 (en) 2011-03-03
PL2265288T3 (pl) 2017-01-31
KR101304085B1 (ko) 2013-09-05
DK2265288T3 (en) 2016-06-06
AU2009220897A1 (en) 2009-09-11
CA2716799C (en) 2018-05-22
US8298536B2 (en) 2012-10-30
KR20100112195A (ko) 2010-10-18
HK1232130A1 (en) 2018-01-05
BRPI0908276B1 (pt) 2020-11-10
CN101959529A (zh) 2011-01-26
EP2265288B1 (en) 2016-05-11
NZ587297A (en) 2012-10-26
RU2010136974A (ru) 2012-03-10
ES2584907T3 (es) 2016-09-30
BRPI0908276B8 (pt) 2021-05-25
AU2009220897B2 (en) 2014-09-18
CA2716799A1 (en) 2009-09-11
JP6363242B2 (ja) 2018-07-25
EP2265288A1 (en) 2010-12-29
US20130295088A1 (en) 2013-11-07
WO2009109908A1 (en) 2009-09-11
US20200148752A1 (en) 2020-05-14
US20170073398A1 (en) 2017-03-16
MX2010009724A (es) 2010-09-28
IL207439A0 (en) 2010-12-30
JP2011513386A (ja) 2011-04-28
RU2467765C2 (ru) 2012-11-27
ZA201006070B (en) 2011-06-29
JP5745861B2 (ja) 2015-07-08
US20220017608A1 (en) 2022-01-20
PT2265288T (pt) 2016-07-14
IL207439B (en) 2019-01-31
EP3115062A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
IL207439A0 (en) Methods of treating inflammatory pain
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0910854A2 (pt) métodos de tratamento
LTC2330892I2 (lt) Gydymo būdai panaudojant vaistus - amoniako gaudykles
BRPI0907135A2 (pt) Processos de tratamento de dor crônica
PT2496691T (pt) Composições de nucleases terapêuticas e métodos
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BR112013011874A2 (pt) compostos e métodos para tratar dor
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
PL3476371T3 (pl) Urządzenie do leczenia gerd
BRPI0917575A2 (pt) métodos de tratamento de talassemia
EP2334315A4 (en) MEANS AND METHOD OF TREATMENT TREATMENT
PT3412687T (pt) Métodos de tratamento de dlbcl
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
PL2435825T3 (pl) Sposoby leczenia chorób
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2330887T3 (da) Behandlingsindretning
PL2621523T3 (pl) Sposoby leczenia choroby autoimmunologicznej z zastosowaniem biokompatybilnych bioabsorbowalnych nanosfer
BRPI0919127A2 (pt) métodos para tratamento de água
EP3381471C0 (en) PAIN TREATMENT
BRPI1014528A2 (pt) compostos para tratamento de inflamação e dor
HRP20170936T1 (hr) Alkilamido spojevi i njihova uporaba
BRPI0917417A2 (pt) mnétodos de tratar deficiência cognitiva
BR112013014915A2 (pt) composição curativa e métodos de tratamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: LABRYS BIOLOGICS INC. (US)

B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF